This site is intended for healthcare professionals

FDA approval for Bylvay, the first drug treatment for patients With progressive familial intrahepatic cholestasis.

Read time: 1 mins
Last updated:21st Jul 2021
Published:21st Jul 2021
-Albireo Pharma, Inc. announced FDA approval of Bylvay (odevixibat), the first drug approved for the treatment of pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), which does not require refrigeration and is easily administered as a once-daily capsule or opened and sprinkled onto soft foods.
Condition: Progressive Familial Intrahepatic Cholestasis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest